Galapagos | GLPG - Ebitda

Stock Price
25.60
Daily Change
-0.34 -1.31%
Monthly
-9.86%
Yearly
15.94%
Q2 Forecast
24.95

Galapagos reported EUR2.42M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
argenx SE USD 387.05M 99.02M Sep/2025
AstraZeneca USD 5.23B 272M Sep/2025
Biogen USD 573.2M 253.7M Dec/2025
Genmab DKK 186M 291M Dec/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
GRIFOLS EUR 347.24M 58.35M Jun/2025
Hikma Pharmaceutical USD 369M 84M Dec/2024
Incyte USD 414.5M 92.42M Dec/2025
Merck EUR 1.44B 263M Dec/2025
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Novartis USD 4.77B 1.11B Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 4.84B 2.95B Sep/2025
UCB EUR 1.6B 570M Dec/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025